2017
DOI: 10.1042/bsr20160447 View full text |Buy / Rent full text
|
|

Abstract: Although, 5-Fluorouracil (5-FU) remains widely used in adjuvant therapy in patients with colon cancer, resistance to 5-FU-based chemotherapy is an important reason for treatment failure. Recent studies have reported that an enhanced reactive oxygen species (ROS) scavenging system shows drug resistance to 5-FU. Peroxiredoxin-2 (PRDX2), is an important member of the ROS scavenging system, and may be a potential target that promotes chemosensitivity to 5-FU in colon cancer. Here, we depleted PRDX2 by PRDX2-shRNA-… Show more

Help me understand this report

Search citation statements

Order By: Relevance
0
0
0
0
0
2
29
0

Publication Types

Select...

Relationship

0
0

Authors

Journals